Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS ...Middle East

TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with...

Hence then, the article about foresee pharmaceuticals announces dosing of first patient in phase 2 3 clinical trial of fp 025 for treatment of covid 19 associated ards was published today ( Sunday 28/03/2021 - 06:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS )

Also on site :

• Trump selling seats on Gaza ‘Board of Peace’ for $1bn
• Thousands rally in Serbia as students continue fight against corruption
• ‘Bringing Up Bates’ Star Katie Clark’s Husband Travis Reveals He Had an Affair